This firm-fixed-price delivery order was awarded by the Department of Veterans Affairs (VA) to Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, to provide the ExoDx Prostate (IntelliScore) test, a non-invasive, urine-based liquid biopsy for assessing the risk of clinically significant prostate cancer. The $521,554.88 contract was issued under the VA's Medical Laboratory Testing and Analysis Services GSA Schedule and has a period of performance through March 2026. This order supports the VA's prostate cancer screening initiatives for veterans and is part of Exosome Diagnostics' broader work with federal healthcare agencies, including multiple delivery orders totaling over $1.2 million under a $1,400,000 VA IDV contract. The company has also participated in federal grant sub-awards focused on advancing extracellular vesicle analysis and liquid biopsy technology for cancer detection and monitoring. There is no set-aside designation for this contract.
Generated 12/18/24, 9:32 AM